Skip to Content

Myriad Genetics Inc MYGN

Rating as of

Morningstar’s Analysis

Currency in USD
Is it the right time to buy or sell?
Find out with Morningstar Premium
Is it the right time to buy or sell?
Find out with Morningstar Premium

1-Star Price


5-Star Price


Economic Moat


Capital Allocation


Taking a Fresh Look at Myriad Genetics; No-Moat Company Remains Overvalued With FVE at 21.50

Karen Andersen, CFA Sector Strategist

Analyst Note

| Karen Andersen, CFA |

After taking a fresh look at Myriad Genetics, we have assigned it with a fair value estimate of $21.50, a no-moat rating, and a stable moat trend. Myriad’s product portfolio includes hereditary cancer, tumor profiling, prenatal, and pharmacogenomics in which Myriad aims to use genetic insights to improve patient care while lowering healthcare costs.

Read Full Analysis

Company Profile

Business Description

Myriad Genetics is a molecular diagnostics company that provides testing services designed to assess an individual’s risk of developing a disease. The firm produces MyRisk, a 35-gene panel with the capability to identify the elevated risk of developing eight types of cancer. Other diagnostic products include BRACAnalysisCDx, the FDA-approved companion diagnostic for PARP inhibitors; GeneSight, which helps improve responses to psychotropic drugs for patients suffering from depression; Prequel, with is a noninvasive prenatal test; and Prolaris, which identifies prostate cancer patients that can pursue active surveillance. The firm offers biomarker discovery and companion diagnostic services to pharma and biotech companies

320 Wakara Way
Salt Lake City, UT, 84108
T +1 801 584-3600
Sector Healthcare
Industry Diagnostics & Research
Most Recent Earnings Sep 30, 2021
Fiscal Year End Dec 31, 2021
Stock Type Distressed
Employees 2,700